Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Reviewing protein intake often reveals deficits that contribute to plateaus
Company : FuturHealth Address : FuturHealth Inc 325 W Washington St Ste 2 - 944 San Diego, CA 92103 Email : [email protected] Phone Support : (831) 900-4723 Disclaimer General Disclaimer This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment
Newer, more potent GLP-1s produce faster weight lossand faster weight loss increases hair loss risk
We provide a transparent, telehealth-first approach that ensures you are never alone in your weight loss journey
For diarrhea, focus on the BRAT diet (bananas, rice, applesauce, toast) during acute episodes